1.78

3.49% 0.06

After Hours: 1.75 -0.03 -1.69%

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $1.78, with a volume of 378.03K. It is up +3.49% in the last 24 hours and up +24.48% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Previous Close:

$1.72

Open:

$1.74

24h Volume:

378.03K

Relative Volume:

0.67

Market Cap:

$76.19M

Revenue:

Net Income/Loss:

$-77.27M

P/E Ratio:

-0.8892

EPS:

-2.0019

Net Cash Flow:

$-66.29M

1W Performance:

+0.00%

1M Performance:

+24.48%

6M Performance:

-40.86%

1Y Performance:

+37.98%

1-Day Range:

$1.719

$1.835

1-Week Range:

$1.705

$1.835

52-Week Range:

$1.2002

$3.56

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

ACRV's Discussions on Twitter

Compare ACRV vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRV Acrivon Therapeutics Inc	1.78	76.19M	0	-77.27M	-66.29M	-2.0019
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-25	Resumed	Piper Sandler	Overweight
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
Dec-15-23	Resumed	Jefferies	Buy
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Jun 27, 2026

Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView

Jun 27, 2026

Jun 26, 2026

Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView

Jun 26, 2026

Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52 - Stock Titan

Jun 22, 2026

Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52 - Stock Titan

Jun 22, 2026

Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options - Stock Titan

Jun 22, 2026

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike - Stock Titan

Jun 22, 2026

Acrivon Therapeutics (ACRV) director granted options on 20,275 shares - Stock Titan

Jun 22, 2026

Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds - Stock Titan

Jun 22, 2026

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 - Stock Titan

Jun 22, 2026

Jun 18, 2026

Acrivon Shareholders Approve Expanded Equity Plan and Directors - The Globe and Mail

Jun 18, 2026

Jun 17, 2026

Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Incentive Plan and Elect New Directors – June 2026 - Minichart

Jun 17, 2026

Acrivon Therapeutics shareholders approve equity plan changes and director elections - Investing.com UK

Jun 17, 2026

Acrivon Therapeutics shareholders approve equity plan changes and director elections By Investing.com - Investing.com India

Jun 17, 2026

Acrivon amends equity plan, shareholders approve 3,000,000-share increase - TradingView

Jun 17, 2026

Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors - Stock Titan

Jun 17, 2026